Labcorp has collaborated with the Alliance for Clinical Trials in Oncology on a new study that seeks to expand access to genetic testing among patients newly diagnosed with colorectal cancer (CRC) and their at-risk family members.
Sponsored by the National Cancer Institute (NCI), the national, multi-centre study will also examine how multigene panel testing could influence treatment and care decisions for these patients.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is designed to assess whether direct outreach by healthcare providers can improve participation in cascade genetic testing among first-degree relatives of CRC patients, many of whom may carry inherited cancer-related variants.
Labcorp will serve as the study’s exclusive genetic testing provider, using its Invitae testing platform to support the trial’s sites across the US, including Puerto Rico.
In addition to investigating cascade testing uptake, the trial will assess the effect of multigene test results on the care of individuals newly diagnosed with colorectal cancer.
Labcorp vice-president and oncology medical lead Shakti Ramkissoon said: “Genetic testing is a critical tool for identifying inherited cancer risk and guiding care for patients and their families, but too often at-risk relatives are not getting tested.
“By supporting this trial and serving as the exclusive genetic testing provider, Labcorp is helping generate real-world evidence on how healthcare providers can connect families to genetic testing and follow-up care.”
The Alliance for Clinical Trials in Oncology is leading and conducting the trial within the NCI National Clinical Trials Network, which includes academic medical centres, community oncology health systems, and NCI-designated cancer centres. The study aims to enrol participants nationwide.
This collaboration forms part of Labcorp’s engagement in genetics-based research to address care gaps for people with cancer while supporting large-scale clinical studies in partnership with research organisations.
